You just read:

Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel Sphingosine 1-Phosphate (S1P) Receptor Modulator

News provided by

Bridge Medicines

Mar 11, 2019, 08:00 ET